{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:31:15Z","timestamp":1793226675493,"version":"4.5.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1038\/s41380-020-0721-9","type":"journal-article","created":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T13:02:48Z","timestamp":1586178168000},"page":"296-308","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":344,"title":["Biomarkers for Alzheimer\u2019s disease\u2014preparing for a new era of disease-modifying therapies"],"prefix":"10.1038","volume":"26","author":[{"given":"Henrik","family":"Zetterberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara B.","family":"Bendlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,6]]},"reference":[{"key":"721_CR1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener. 2019;14:32.","journal-title":"Mol Neurodegener."},{"key":"721_CR2","doi-asserted-by":"crossref","first-page":"e11170","DOI":"10.15252\/emmm.201911170","volume":"11","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease. EMBO Mol Med. 2019;11:e11170.","journal-title":"EMBO Mol Med"},{"key":"721_CR3","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.neuron.2013.12.003","volume":"80","author":"CR Jack Jr.","year":"2013","unstructured":"Jack CR Jr., Holtzman DM. Biomarker modeling of Alzheimer\u2019s disease. Neuron. 2013;80:1347\u201358.","journal-title":"Neuron."},{"key":"721_CR4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science. 1992;256:184\u20135.","journal-title":"Science."},{"key":"721_CR5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","volume":"164","author":"B De Strooper","year":"2016","unstructured":"De Strooper B, Karran E. The cellular phase of Alzheimer\u2019s disease. Cell. 2016;164:603\u201315.","journal-title":"Cell"},{"key":"721_CR6","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.celrep.2019.03.099","volume":"27","author":"C Sala Frigerio","year":"2019","unstructured":"Sala Frigerio C, Wolfs L, Fattorelli N, Thrupp N, Voytyuk I, Schmidt I, et al. The major risk factors for Alzheimer\u2019s disease: age, sex, and genes modulate the microglia response to abeta plaques. Cell Rep. 2019;27:1293\u2013306. e6.","journal-title":"Cell Rep."},{"key":"721_CR7","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/s41582-018-0070-3","volume":"14","author":"M Kivipelto","year":"2018","unstructured":"Kivipelto M, Mangialasche F, Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol. 2018;14:653\u201366.","journal-title":"Nat Rev Neurol"},{"key":"721_CR8","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/joim.12959","volume":"286","author":"R Loera-Valencia","year":"2019","unstructured":"Loera-Valencia R, Cedazo-Minguez A, Kenigsberg PA, Page G, Duarte AI, Giusti P, et al. Current and emerging avenues for Alzheimer\u2019s disease drug targets. J Intern Med. 2019;286:398\u2013437.","journal-title":"J Intern Med"},{"key":"721_CR9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/B978-0-12-385883-2.00012-6","volume":"107","author":"DM Walsh","year":"2012","unstructured":"Walsh DM, Teplow DB. Alzheimer\u2019s disease and the amyloid beta-protein. Prog Mol Biol Transl Sci. 2012;107:101\u201324.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"721_CR10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12929-019-0609-7","volume":"27","author":"LK Huang","year":"2020","unstructured":"Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020;27:18.","journal-title":"J Biomed Sci"},{"key":"721_CR11","doi-asserted-by":"publisher","unstructured":"Suidan GL, Ramaswamy G. Targeting apolipoprotein E for Alzheimer\u2019s disease: an industry perspective. Int J Mol Sci. 2019;20:2161. https:\/\/doi.org\/10.3390\/ijms20092161.","DOI":"10.3390\/ijms20092161"},{"key":"721_CR12","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","volume":"5","author":"J Cummings","year":"2019","unstructured":"Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer\u2019s disease drug development pipeline: 2019. Alzheimers Dement. 2019;5:272\u201393.","journal-title":"Alzheimers Dement"},{"key":"721_CR13","doi-asserted-by":"crossref","first-page":"104707","DOI":"10.1016\/j.nbd.2019.104707","volume":"134","author":"A Bittar","year":"2020","unstructured":"Bittar A, Bhatt N, Kayed R. Advances and considerations in AD tau-targeted immunotherapy. Neurobiol Dis. 2020;134:104707.","journal-title":"Neurobiol Dis."},{"key":"721_CR14","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med. 2016;8:595\u2013608.","journal-title":"EMBO Mol Med"},{"key":"721_CR15","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","volume":"12","author":"J Hardy","year":"1991","unstructured":"Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease. Trends Pharm Sci. 1991;12:383\u20138.","journal-title":"Trends Pharm Sci"},{"key":"721_CR16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.mcn.2018.12.004","volume":"97","author":"AD Cohen","year":"2019","unstructured":"Cohen AD, Landau SM, Snitz BE, Klunk WE, Blennow K, Zetterberg H. Fluid and PET biomarkers for amyloid pathology in Alzheimer\u2019s disease. Mol Cell Neurosci. 2019;97:3\u201317.","journal-title":"Mol Cell Neurosci"},{"key":"721_CR17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15:673\u201384.","journal-title":"Lancet Neurol."},{"key":"721_CR18","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S1474-4422(18)30318-1","volume":"17","author":"MK Rasmussen","year":"2018","unstructured":"Rasmussen MK, Mestre H, Nedergaard M. The glymphatic pathway in neurological disorders. Lancet Neurol. 2018;17:1016\u201324.","journal-title":"Lancet Neurol."},{"key":"721_CR19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","volume":"11","author":"O Hansson","year":"2019","unstructured":"Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and disadvantages of the use of the CSF amyloid beta (Abeta) 42\/40 ratio in the diagnosis of Alzheimer\u2019s Disease. Alzheimers Res Ther. 2019;11:34.","journal-title":"Alzheimers Res Ther"},{"key":"721_CR20","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3233\/JAD-160722","volume":"55","author":"P Lewczuk","year":"2017","unstructured":"Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, et al. Cerebrospinal fluid abeta42\/40 corresponds better than abeta42 to amyloid PET in Alzheimer\u2019s disease. J Alzheimers Dis. 2017;55:813\u201322.","journal-title":"J Alzheimers Dis"},{"key":"721_CR21","doi-asserted-by":"publisher","unstructured":"Mattsson N, Palmqvist S, Stomrud E, Vogel J, Hansson O. Staging beta-amyloid pathology with amyloid positron emission tomography. JAMA Neurol. 2019;76. https:\/\/doi.org\/10.1001\/jamaneurol.2019.2214 [Online ahead of print].","DOI":"10.1001\/jamaneurol.2019.2214"},{"key":"721_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr., Jagust WJ, et al. The centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1\u201315. e1\u20134.","journal-title":"Alzheimers Dement."},{"key":"721_CR23","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/j.jalz.2013.06.001","volume":"9","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid imaging task force of the Alzheimer\u2019s association and society for nuclear medicine and molecular imaging. Alzheimers Dement. 2013;9:e106\u20139.","journal-title":"Alzheimers Dement."},{"key":"721_CR24","volume-title":"Assessing the preparedness of the U.S. health care system infrastructure for an Alzheimer\u2019s treatment","author":"JL Liu","year":"2017","unstructured":"Liu JL, Hlavka JP, Hillestad R, Mattke S. Assessing the preparedness of the U.S. health care system infrastructure for an Alzheimer\u2019s treatment. Santa Monica, CA: RAND Corporation; 2017."},{"key":"721_CR25","volume-title":"Assessing the preparedness of the Canadian health care system infrastructure for an Alzheimer\u2019s treatment","author":"JL Liu","year":"2019","unstructured":"Liu JL, Hlavka JP, Coulter DT, Baxi SM, Mattke S, Gidengil CA. Assessing the preparedness of the Canadian health care system infrastructure for an Alzheimer\u2019s treatment. Santa Monica, CA: RAND Corporation; 2019."},{"key":"721_CR26","doi-asserted-by":"crossref","DOI":"10.7249\/RR2503","volume-title":"Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer\u2019s treatment","author":"JP Hlavka","year":"2018","unstructured":"Hlavka JP, Mattke S, Liu JL. Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer\u2019s treatment. Santa Monica, CA: RAND Corporation; 2018."},{"key":"721_CR27","volume-title":"Assessing the preparedness of the Japanese health care system infrastructure for an Alzheimer\u2019s treatment","author":"S Mattke","year":"2019","unstructured":"Mattke S, Hl\u00e1vka JP, Yoong J, Wang M, Goto R. Assessing the preparedness of the Japanese health care system infrastructure for an Alzheimer\u2019s treatment. Santa Monica, CA: RAND Corporation; 2019."},{"key":"721_CR28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3233\/JAD-160573","volume":"55","author":"SP Arneric","year":"2017","unstructured":"Arneric SP, Batrla-Utermann R, Beckett L, Bittner T, Blennow K, Carter L, et al. Cerebrospinal fluid biomarkers for Alzheimer\u2019s disease: a view of the regulatory science qualification landscape from the coalition against major diseases CSF biomarker team. J Alzheimers Dis. 2017;55:19\u201335.","journal-title":"J Alzheimers Dis"},{"key":"721_CR29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cca.2016.05.014","volume":"467","author":"J Kuhlmann","year":"2017","unstructured":"Kuhlmann J, Andreasson U, Pannee J, Bjerke M, Portelius E, Leinenbach A, et al. CSF abeta1-42\u2014an excellent but complicated Alzheimer\u2019s biomarker\u2014a route to standardisation. Clin Chim Acta. 2017;467:27\u201333.","journal-title":"Clin Chim Acta"},{"key":"721_CR30","doi-asserted-by":"crossref","DOI":"10.1038\/srep26801","volume":"6","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, et al. Plasma beta-amyloid in Alzheimer\u2019s disease and vascular disease. Sci Rep. 2016;6:26801.","journal-title":"Sci Rep."},{"key":"721_CR31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V, et al. High performance plasma amyloid-beta biomarkers for Alzheimer\u2019s disease. Nature. 2018;554:249\u201354.","journal-title":"Nature."},{"key":"721_CR32","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, et al. Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13:841\u20139.","journal-title":"Alzheimers Dement"},{"key":"721_CR33","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma beta-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93:e1647\u201359.","journal-title":"Neurology."},{"key":"721_CR34","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","volume":"76","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status. JAMA Neurol. 2019;76:1060\u20139.","journal-title":"JAMA Neurol"},{"issue":"Suppl 1","key":"721_CR35","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.parkreldis.2015.09.020","volume":"22","author":"DJ Irwin","year":"2016","unstructured":"Irwin DJ. Tauopathies as clinicopathological entities. Parkinsonism Relat Disord 2016;22 Suppl 1:S29\u201333.","journal-title":"Parkinsonism Relat Disord"},{"key":"721_CR36","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr.","year":"2018","unstructured":"Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"721_CR37","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614\u201329.","journal-title":"Lancet Neurol."},{"key":"721_CR38","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ana.1054","volume":"50","author":"N Itoh","year":"2001","unstructured":"Itoh N, Arai H, Urakami K, Ishiguro K, Ohno H, Hampel H, et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer\u2019s disease. Ann Neurol. 2001;50:150\u20136.","journal-title":"Ann Neurol."},{"key":"721_CR39","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1093\/brain\/awv181","volume":"138","author":"T Skillback","year":"2015","unstructured":"Skillback T, Farahmand BY, Rosen C, Mattsson N, Nagga K, Kilander L, et al. Cerebrospinal fluid tau and amyloid-beta(1-42) in patients with dementia. Brain. 2015;138:2716\u201331.","journal-title":"Brain."},{"key":"721_CR40","first-page":"194re2","volume":"5","author":"LF Maia","year":"2013","unstructured":"Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M, et al. Changes in amyloid-beta and tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med. 2013;5:194re2.","journal-title":"Sci Transl Med"},{"key":"721_CR41","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.neuron.2018.04.035","volume":"98","author":"C Sato","year":"2018","unstructured":"Sato C, Barthelemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel-Balsarotti J, et al. Tau kinetics in neurons and the human central nervous system. Neuron. 2018;98:861\u20134.","journal-title":"Neuron."},{"key":"721_CR42","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13195-019-0550-8","volume":"11","author":"MJ Leitao","year":"2019","unstructured":"Leitao MJ, Silva-Spinola A, Santana I, Olmedo V, Nadal A, Le Bastard N, et al. Clinical validation of the lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer\u2019s disease. Alzheimers Res Ther. 2019;11:91.","journal-title":"Alzheimers Res Ther"},{"key":"721_CR43","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54204-z","volume":"9","author":"K Blennow","year":"2019","unstructured":"Blennow K, Shaw LM, Stomrud E, Mattsson N, Toledo JB, Buck K, et al. Predicting clinical decline and conversion to Alzheimer\u2019s disease or dementia using novel Elecsys Abeta(1-42), pTau and tTau CSF immunoassays. Sci Rep. 2019;9:19024.","journal-title":"Sci Rep."},{"key":"721_CR44","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-017-0945-8","volume":"17","author":"A De Vos","year":"2017","unstructured":"De Vos A, Bjerke M, Brouns R, De Roeck N, Jacobs D, Van den Abbeele L, et al. Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke. BMC Neurol. 2017;17:170.","journal-title":"BMC Neurol."},{"key":"721_CR45","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1089\/neu.2015.4333","volume":"34","author":"T Bogoslovsky","year":"2017","unstructured":"Bogoslovsky T, Wilson D, Chen Y, Hanlon D, Gill J, Jeromin A, et al. Increases of plasma levels of glial fibrillary acidic protein, tau, and amyloid beta up to 90 days after traumatic brain injury. J Neurotrauma. 2017;34:66\u201373.","journal-title":"J Neurotrauma"},{"key":"721_CR46","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/nan.12378","volume":"43","author":"H Zetterberg","year":"2017","unstructured":"Zetterberg H. Review: tau in biofluids\u2014relation to pathology, imaging and clinical features. Neuropathol Appl Neurobiol. 2017;43:194\u20139.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"721_CR47","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.neurobiolaging.2017.06.002","volume":"58","author":"JB Pereira","year":"2017","unstructured":"Pereira JB, Westman E, Hansson O, Alzheimer\u2019s Disease Neuroimaging I. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer\u2019s disease. Neurobiol Aging. 2017;58:14\u201329.","journal-title":"Neurobiol Aging."},{"key":"721_CR48","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.resuscitation.2012.07.027","volume":"84","author":"J Randall","year":"2013","unstructured":"Randall J, Mortberg E, Provuncher GK, Fournier DR, Duffy DC, Rubertsson S, et al. Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study. Resuscitation. 2013;84:351\u20136.","journal-title":"Resuscitation."},{"key":"721_CR49","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al. Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 2018;14:989\u201397.","journal-title":"Alzheimers Dement."},{"key":"721_CR50","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med. 2020;26:387\u201397.","journal-title":"Nat Med"},{"key":"721_CR51","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Insel P, Smith R, Eichenlaub U, et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med. 2020;26:379\u201386.","journal-title":"Nat Med"},{"key":"721_CR52","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239\u201359.","journal-title":"Acta Neuropathol."},{"key":"721_CR53","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13024-017-0162-3","volume":"12","author":"L Saint-Aubert","year":"2017","unstructured":"Saint-Aubert L, Lemoine L, Chiotis K, Leuzy A, Rodriguez-Vieitez E, Nordberg A, et al. imaging: present and future directions. Mol Neurodegener. 2017;12:19.","journal-title":"Mol Neurodegener"},{"key":"721_CR54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13195-017-0253-y","volume":"9","author":"KP Ng","year":"2017","unstructured":"Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, et al. Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain. Alzheimers Res Ther. 2017;9:25.","journal-title":"Alzheimers Res Ther"},{"key":"721_CR55","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/bs.pmbts.2019.07.007","volume":"165","author":"TJ Betthauser","year":"2019","unstructured":"Betthauser TJ. AD molecular: imaging tau aggregates with positron emissions tomography. Prog Mol Biol Transl Sci. 2019;165:107\u201338.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"721_CR56","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00401-017-1740-8","volume":"134","author":"M Marquie","year":"2017","unstructured":"Marquie M, Siao Tick Chong M, Anton-Fernandez A, Verwer EE, Saez-Calveras N, Meltzer AC. et al. [F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging. Acta Neuropathol.2017;134:619\u201328.","journal-title":"Acta Neuropathol."},{"key":"721_CR57","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ana.24844","volume":"81","author":"M Marquie","year":"2017","unstructured":"Marquie M, Normandin MD, Meltzer AC, Siao Tick Chong M, Andrea NV, Anton-Fernandez A. et al. Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies. Ann Neurol.2017;81:117\u201328.","journal-title":"Ann Neurol."},{"key":"721_CR58","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2967\/jnumed.118.209650","volume":"60","author":"TJ Betthauser","year":"2019","unstructured":"Betthauser TJ, Cody KA, Zammit MD, Murali D, Converse AK, Barnhart TE, et al. In vivo characterization and quantification of neurofibrillary tau PET radioligand (18)F-MK-6240 in humans from Alzheimer disease dementia to young controls. J Nucl Med. 2019;60:93\u20139.","journal-title":"J Nucl Med"},{"key":"721_CR59","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.2967\/jnumed.118.214437","volume":"59","author":"H Kuwabara","year":"2018","unstructured":"Kuwabara H, Comley RA, Borroni E, Honer M, Kitmiller K, Roberts J, et al. Evaluation of (18)F-RO-948 PET for quantitative assessment of tau accumulation in the human brain. J Nucl Med. 2018;59:1877\u201384.","journal-title":"J Nucl Med"},{"key":"721_CR60","doi-asserted-by":"publisher","unstructured":"Mueller A, Bullich S, Barret O, Madonia J, Berndt M, Papin C, et al. Tau PET imaging with (18)F-PI-2620 in patients with Alzheimer\u2019s disease and healthy controls: a first-in-human study. J Nucl Med. 2019. https:\/\/doi.org\/10.2967\/jnumed.119.236224. [Online ahead of print].","DOI":"10.2967\/jnumed.119.236224"},{"key":"721_CR61","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s00259-019-04399-0","volume":"46","author":"S Sanabria Bohorquez","year":"2019","unstructured":"Sanabria Bohorquez S, Marik J, Ogasawara A, Tinianow JN, Gill HS, Barret O, et al. [(18)F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2019;46:2077\u201389.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"721_CR62","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.mcn.2018.12.001","volume":"97","author":"M Scholl","year":"2019","unstructured":"Scholl M, Maass A, Mattsson N, Ashton NJ, Blennow K, Zetterberg H, et al. Biomarkers for tau pathology. Mol Cell Neurosci. 2019;97:18\u201333.","journal-title":"Mol Cell Neurosci"},{"key":"721_CR63","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrneurol.2009.215","volume":"6","author":"GB Frisoni","year":"2010","unstructured":"Frisoni GB, Fox NC, Jack CR Jr., Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6:67\u201377.","journal-title":"Nat Rev Neurol"},{"key":"721_CR64","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(99)00496-1","volume":"353","author":"NC Fox","year":"1999","unstructured":"Fox NC, Warrington EK, Rossor MN. Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer\u2019s disease. Lancet. 1999;353:2125.","journal-title":"Lancet."},{"key":"721_CR65","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1212\/WNL.42.1.183","volume":"42","author":"CR Jack Jr.","year":"1992","unstructured":"Jack CR Jr., Petersen RC, O\u2019Brien PC, Tangalos EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer\u2019s disease. Neurology. 1992;42:183\u20138.","journal-title":"Neurology."},{"key":"721_CR66","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1212\/WNL.0b013e3182166e96","volume":"76","author":"BC Dickerson","year":"2011","unstructured":"Dickerson BC, Stoub TR, Shah RC, Sperling RA, Killiany RJ, Albert MS, et al. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology. 2011;76:1395\u2013402.","journal-title":"Neurology."},{"key":"721_CR67","doi-asserted-by":"publisher","unstructured":"Vogt NM, Hunt JF, Adluru N, Dean DC, Johnson SC, Asthana S, et al. Cortical microstructural alterations in mild cognitive impairment and Alzheimer\u2019s disease dementia. Cereb Cortex. 2019. https:\/\/doi.org\/10.1093\/cercor\/bhz286. [Online ahead of print].","DOI":"10.1093\/cercor\/bhz286"},{"key":"721_CR68","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577\u201389.","journal-title":"Nat Rev Neurol"},{"key":"721_CR69","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90:870\u201381.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"721_CR70","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","volume":"76","author":"C Bridel","year":"2019","unstructured":"Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, and the NFLG, et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 2019;76:1035\u201348.","journal-title":"JAMA Neurol"},{"key":"721_CR71","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13195-019-0472-5","volume":"11","author":"PSJ Weston","year":"2019","unstructured":"Weston PSJ, Poole T, O\u2019Connor A, Heslegrave A, Ryan NS, Liang Y, et al. Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer\u2019s disease. Alzheimers Res Ther. 2019;11:19.","journal-title":"Alzheimers Res Ther"},{"key":"721_CR72","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat Med. 2019;25:277\u201383.","journal-title":"Nat Med"},{"key":"721_CR73","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2019;76:791\u20139.","journal-title":"JAMA Neurol"},{"key":"721_CR74","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572\u201380.","journal-title":"Ann Neurol."},{"key":"721_CR75","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1176\/appi.ajp.159.5.738","volume":"159","author":"GE Alexander","year":"2002","unstructured":"Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer\u2019s disease treatment studies. Am J Psychiatry. 2002;159:738\u201345.","journal-title":"Am J Psychiatry"},{"issue":"Suppl 1","key":"721_CR76","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.neurobiolaging.2011.09.007","volume":"32","author":"EM Reiman","year":"2011","unstructured":"Reiman EM. Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer\u2019s disease-modifying treatments. Neurobiol Aging. 2011;32 Suppl 1:S44\u20137.","journal-title":"Neurobiol Aging."},{"key":"721_CR77","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nn.4492","volume":"20","author":"ER Zimmer","year":"2017","unstructured":"Zimmer ER, Parent MJ, Souza DG, Leuzy A, Lecrux C, Kim HI, et al. [(18)F]FDG PET signal is driven by astroglial glutamate transport. Nat Neurosci. 2017;20:393\u20135.","journal-title":"Nat Neurosci."},{"key":"721_CR78","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jamaneurol.2018.1836","volume":"75","author":"MK Chen","year":"2018","unstructured":"Chen MK, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin SF, et al. Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging. JAMA Neurol. 2018;75:1215\u201324.","journal-title":"JAMA Neurol"},{"key":"721_CR79","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11307-018-1260-5","volume":"21","author":"CC Constantinescu","year":"2019","unstructured":"Constantinescu CC, Tresse C, Zheng M, Gouasmat A, Carroll VM, Mistico L, et al. Development and in vivo preclinical imaging of fluorine-18-labeled synaptic vesicle protein 2A (SV2A) PET tracers. Mol Imaging Biol. 2019;21:509\u201318.","journal-title":"Mol Imaging Biol"},{"key":"721_CR80","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1007\/s00259-019-04357-w","volume":"46","author":"S Li","year":"2019","unstructured":"Li S, Cai Z, Zhang W, Holden D, Lin SF, Finnema SJ, et al. Synthesis and in vivo evaluation of [(18)F]UCB-J for PET imaging of synaptic vesicle glycoprotein 2A (SV2A). Eur J Nucl Med Mol Imaging. 2019;46:1952\u201365.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"721_CR81","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.jalz.2014.10.009","volume":"11","author":"H Kvartsberg","year":"2015","unstructured":"Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Ohrfelt A, Andersson K, et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer\u2019s disease. Alzheimers Dement. 2015;11:1180\u201390.","journal-title":"Alzheimers Dement"},{"key":"721_CR82","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1212\/WNL.0000000000002423","volume":"86","author":"H Wellington","year":"2016","unstructured":"Wellington H, Paterson RW, Portelius E, Tornqvist U, Magdalinou N, Fox NC, et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. 2016;86:829\u201335.","journal-title":"Neurology."},{"key":"721_CR83","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00401-018-1851-x","volume":"136","author":"E Portelius","year":"2018","unstructured":"Portelius E, Olsson B, Hoglund K, Cullen NC, Kvartsberg H, Andreasson U, et al. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol. 2018;136:363\u201376.","journal-title":"Acta Neuropathol."},{"key":"721_CR84","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1212\/WNL.0000000000004569","volume":"89","author":"KB Casaletto","year":"2017","unstructured":"Casaletto KB, Elahi FM, Bettcher BM, Neuhaus J, Bendlin BB, Asthana S, et al. Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers. Neurology. 2017;89:1782\u20138.","journal-title":"Neurology."},{"key":"721_CR85","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.jalz.2015.05.012","volume":"11","author":"A De Vos","year":"2015","unstructured":"De Vos A, Jacobs D, Struyfs H, Fransen E, Andersson K, Portelius E, et al. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer\u2019s disease. Alzheimers Dement. 2015;11:1461\u20139.","journal-title":"Alzheimers Dement."},{"key":"721_CR86","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13024-018-0298-9","volume":"13","author":"M Gratuze","year":"2018","unstructured":"Gratuze M, Leyns CEG, Holtzman DM. New insights into the role of TREM2 in Alzheimer\u2019s disease. Mol Neurodegener. 2018;13:66.","journal-title":"Mol Neurodegener."},{"key":"721_CR87","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00401-018-1932-x","volume":"136","author":"JL Molinuevo","year":"2018","unstructured":"Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, Cummings J, et al. Current state of Alzheimer\u2019s fluid biomarkers. Acta Neuropathol. 2018;136:821\u201353.","journal-title":"Acta Neuropathol"},{"key":"721_CR88","doi-asserted-by":"crossref","first-page":"466","DOI":"10.15252\/emmm.201506123","volume":"8","author":"M Suarez-Calvet","year":"2016","unstructured":"Suarez-Calvet M, Kleinberger G, Araque Caballero MA, Brendel M, Rominger A, Alcolea D, et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer\u2019s disease and associate with neuronal injury markers. EMBO Mol Med. 2016;8:466\u201376.","journal-title":"EMBO Mol Med"},{"key":"721_CR89","doi-asserted-by":"publisher","unstructured":"Elahi FM, Casaletto KB, La Joie R, Walters SM, Harvey D, Wolf A, et al. Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer\u2019s disease. Alzheimers Dement. 2019. https:\/\/doi.org\/10.1016\/j.jalz.2019.09.004. [Online ahead of print].","DOI":"10.1016\/j.jalz.2019.09.004"},{"key":"721_CR90","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2967\/jnumed.110.086629","volume":"52","author":"AM Scarf","year":"2011","unstructured":"Scarf AM, Kassiou M. The translocator protein. J Nucl Med. 2011;52:677\u201380.","journal-title":"J Nucl Med"},{"key":"721_CR91","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1093\/brain\/awx120","volume":"140","author":"P Parbo","year":"2017","unstructured":"Parbo P, Ismail R, Hansen KV, Amidi A, Marup FH, Gottrup H, et al. Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer\u2019s disease. Brain. 2017;140:2002\u201311.","journal-title":"Brain."},{"key":"721_CR92","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1212\/01.wnl.0000244749.20056.d4","volume":"68","author":"P Edison","year":"2007","unstructured":"Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007;68:501\u20138.","journal-title":"Neurology."},{"key":"721_CR93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jcbfm.2011.147","volume":"32","author":"DR Owen","year":"2012","unstructured":"Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012;32:1\u20135.","journal-title":"J Cereb Blood Flow Metab"},{"key":"721_CR94","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/jnnp-2018-319148","volume":"90","author":"XN Shen","year":"2019","unstructured":"Shen XN, Niu LD, Wang YJ, Cao XP, Liu Q, Tan L, et al. Inflammatory markers in Alzheimer\u2019s disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies. J Neurol Neurosurg Psychiatry. 2019;90:590\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"721_CR95","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1093\/brain\/awy146","volume":"141","author":"JL Robinson","year":"2018","unstructured":"Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;141:2181\u201393.","journal-title":"Brain."},{"key":"721_CR96","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1093\/brain\/aww224","volume":"139","author":"BD James","year":"2016","unstructured":"James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. TDP-43 stage, mixed pathologies, and clinical Alzheimer\u2019s-type dementia. Brain. 2016;139:2983\u201393.","journal-title":"Brain."},{"issue":"(Suppl 1)","key":"721_CR97","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/S1353-8020(13)70020-8","volume":"20","author":"B Mollenhauer","year":"2014","unstructured":"Mollenhauer B. Quantification of alpha-synuclein in cerebrospinal fluid: how ideal is this biomarker for Parkinson\u2019s disease? Parkinsonism Relat Disord. 2014;20(Suppl 1):S76\u20139.","journal-title":"Parkinsonism Relat Disord"},{"key":"721_CR98","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3389\/fneur.2018.00415","volume":"9","author":"S Paciotti","year":"2018","unstructured":"Paciotti S, Bellomo G, Gatticchi L, Parnetti L. Are we ready for detecting alpha-synuclein prone to aggregation in patients? the case of \u201cprotein-misfolding cyclic amplification\u201d and \u201creal-time quaking-induced conversion\u201d as diagnostic tools. Front Neurol. 2018;9:415.","journal-title":"Front Neurol."},{"key":"721_CR99","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","volume":"74","author":"M Shahnawaz","year":"2017","unstructured":"Shahnawaz M, Tokuda T, Waragai M, Mendez N, Ishii R, Trenkwalder C, et al. Development of a biochemical diagnosis of parkinson disease by detection of alpha-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol. 2017;74:163\u201372.","journal-title":"JAMA Neurol"},{"key":"721_CR100","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/acn3.338","volume":"3","author":"G Fairfoul","year":"2016","unstructured":"Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol. 2016;3:812\u20138.","journal-title":"Ann Clin Transl Neurol"},{"key":"721_CR101","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-018-0508-2","volume":"6","author":"BR Groveman","year":"2018","unstructured":"Groveman BR, Orru CD, Hughson AG, Raymond LD, Zanusso G, Ghetti B, et al. Rapid and ultra-sensitive quantitation of disease-associated alpha-synuclein seeds in brain and cerebrospinal fluid by alphaSyn RT-QuIC. Acta Neuropathol Commun. 2018;6:7.","journal-title":"Acta Neuropathol Commun"},{"key":"721_CR102","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr.","year":"2013","unstructured":"Jack CR Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207\u201316.","journal-title":"Lancet Neurol."},{"key":"721_CR103","doi-asserted-by":"crossref","first-page":"369ra178","DOI":"10.1126\/scitranslmed.aag1767","volume":"8","author":"M Suarez-Calvet","year":"2016","unstructured":"Suarez-Calvet M, Araque Caballero MA, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, et al. Early changes in CSF sTREM2 in dominantly inherited Alzheimer\u2019s disease occur after amyloid deposition and neuronal injury. Sci Transl Med. 2016;8:369ra178.","journal-title":"Sci Transl Med"},{"key":"721_CR104","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jalz.2018.03.005","volume":"14","author":"R Brookmeyer","year":"2018","unstructured":"Brookmeyer R, Abdalla N. Estimation of lifetime risks of Alzheimer\u2019s disease dementia using biomarkers for preclinical disease. Alzheimers Dement. 2018;14:981\u20138.","journal-title":"Alzheimers Dement."},{"key":"721_CR105","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/jnen\/nlw002","volume":"75","author":"A Elobeid","year":"2016","unstructured":"Elobeid A, Libard S, Leino M, Popova SN, Alafuzoff I. Altered proteins in the aging brain. J Neuropathol Exp Neurol. 2016;75:316\u201325.","journal-title":"J Neuropathol Exp Neurol"},{"key":"721_CR106","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1212\/WNL.0b013e3182477eed","volume":"78","author":"N Mattsson","year":"2012","unstructured":"Mattsson N, Rosen E, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology. 2012;78:468\u201376.","journal-title":"Neurology."},{"key":"721_CR107","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1552-6569.2001.tb00068.x","volume":"11","author":"Y Tang","year":"2001","unstructured":"Tang Y, Whitman GT, Lopez I, Baloh RW. Brain volume changes on longitudinal magnetic resonance imaging in normal older people. J Neuroimaging. 2001;11:393\u2013400.","journal-title":"J Neuroimaging"},{"key":"721_CR108","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1017\/S1041610209991396","volume":"22","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Qiu C, Lindberg O, Bronge L, Aspelin P, Backman L, et al. Acceleration of hippocampal atrophy in a non-demented elderly population: the SNAC-K study. Int Psychogeriatr. 2010;22:14\u201325.","journal-title":"Int Psychogeriatr"},{"key":"721_CR109","unstructured":"Haeberlein SB, von Hehn C, Tian Y, Chalkias S, Muralidharan KK, Chen T, et al. Topline results from phase 3 aducanumab studies clinical trials on Alzheimer\u2019s disease. Abstract and presentation at CTAD2019, San Diego; 2019."}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41380-020-0721-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41380-020-0721-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41380-020-0721-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:01:37Z","timestamp":1684602097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-020-0721-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,6]]},"references-count":109,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["721"],"URL":"https:\/\/doi.org\/10.1038\/s41380-020-0721-9","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,6]]},"assertion":[{"value":"2 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. BBB has received precursors and imaging agents from Avid Radiopharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}